

LISTING OF THE CLAIMS

1. (Previously Presented) A transdermal delivery system comprising an ethoxylated oil and a delivered agent formulated in the absence of alcohol.
2. (Original) The transdermal delivery system of Claim 1, further comprising water.
3. (Canceled)
4. (Previously Presented) The transdermal delivery system of Claim 1, wherein said ethoxylated oil comprises an ethoxylated animal oil or an ethoxylated vegetable oil.
5. (Previously Presented) The transdermal delivery system of Claim 1, wherein said ethoxylated oil comprises an oil selected from the group consisting of ethoxylated castor oil, ethoxylated jojoba oil, ethoxylated corn oil, and ethoxylated emu oil.
6. (Previously Presented) The transdermal delivery system of Claim 1, wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).
7. (Original) The transdermal delivery system of Claim 1, wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6 - pteridinyl - methyl] methylamino] benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-NN-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (-)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fuoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; diflunisal (2',4', -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1, 2-benzothiazine-2-carboxamide 1, 1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2, 6-dichloro-m-tolyl)anthranilic acid, sodium salt, monohydrate); ketoprofen (2- (3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino] benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{{4-[(7-chloro-4-quinolyl) amino] pentyl} ethylamino}ethanol sulfate (1:1); penicillamine (3-mercaptop-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+.)); cetadolac (1-8- diethyl-13,4,9, tetra hydroprano-[3-4-13] indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N, N-di-methylethamine hydrochloride).

Appl. No. : 10/789,836
Filed : February 27, 2004

8. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent is a protein or fragment thereof.

9. (Previously Presented) The transdermal delivery system of Claim 8, wherein the delivered agent is a collagen or a fragment thereof.

10. (Previously Presented) The transdermal delivery system of Claim 8, wherein the delivered agent has an approximate average molecular weight of less than or equal to 1,000 daltons.

11. (Original) The transdermal delivery system of Claim 9, wherein the collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.

12. (Original) The transdermal delivery system of Claim 9, wherein the collagen has an approximate average molecular weight of about 2,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.

13. (Original) The transdermal delivery system of Claim 9, wherein the collagen has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.

14. (Original) The transdermal delivery system of Claim 9, wherein the collagen has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.

15. (Original) A method of reducing pain or inflammation comprising:
identifying a subject in need of a reduction in pain or inflammation; and
providing said subject a transdermal delivery system according to Claim 1.

16. (Original) The method of Claim 15, wherein said transdermal delivery system further comprises water.

17. (Canceled)

18. (Previously Presented) The method of Claim 15, wherein said ethoxylated oil comprises an ethoxylated animal oil or an ethoxylated vegetable oil.

19. (Previously Presented) The method of Claim 15, wherein said ethoxylated oil comprises an oil selected from the group consisting of ethoxylated castor oil, ethoxylated jojoba oil, ethoxylated corn oil, and ethoxylated emu oil.

20. (Previously Presented) The method of Claim 15, wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).

21. (Original) The method of Claim 15, wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6 - pteridinyl - methyl] methylamino] benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-NN-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (-)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fuoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; diflunisal (2',4', -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1, 2-benzothiazine-2-carboxamide 1, 1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2, 6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2- (3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino] benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl) amino] pentyl] ethylamino}ethanol sulfate (1:1); penicillamine (3-mercaptop-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+-.)); cetodolac (1-8- diethyl-13,4,9, tetra hydropyrano-[3-4-13] indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N, N-di-methylethamine hydrochloride).

22-23. (Canceled)

24. (Previously Presented) A method of reducing wrinkles in the skin comprising:
identifying a subject in need of skin tone restoration; and
providing to said subject a transdermal delivery system according to Claim 9.

25. (Original) The method of Claim 24, wherein said delivery system further comprises water.

26. (Canceled)

27. (Previously Presented) The method of Claim 24, wherein said ethoxylated oil comprises an ethoxylated animal oil or an ethoxylated vegetable oil.

28. (Previously Presented) The method of Claim 24, wherein said ethoxylated oil comprises an oil selected from the group consisting of ethoxylated castor oil, ethoxylated jojoba oil, ethoxylated corn oil, and ethoxylated emu oil.

Appl. No. : 10/789,836
Filed : February 27, 2004

29. (Previously Presented) The method of Claim 24, wherein said delivered agent is a protein or fragment thereof.

30. (Previously Presented) The method of Claim 29, wherein the delivered agent has an approximate average molecular weight of less than or equal to 1,000 daltons.

31. (Previously Presented) The method of Claim 29, wherein the delivered agent is a collagen.

32. (Original) The method of Claim 31, wherein said collagen has an approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.

33. (Original) The method of Claim 31, wherein said collagen has an approximate average molecular weight of about 2,000 daltons.

34. (Original) The method of Claim 31, wherein said collagen has an approximate average molecular weight of about 300,000 daltons and the therapeutically effective amount is 0.1% to 2.0%.

35. (Original) The method of Claim 31, wherein said collagen has an approximate average molecular weight of about 500,000 daltons and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.

36. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 2,000,000 daltons.

37. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 2,000 daltons to about 500,000 daltons.

38. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 6,500 daltons to about 205,000 daltons.

39. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 100,000 daltons.

40. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 300,000 daltons to about 500,000 daltons.

41. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight greater than about 6,000 daltons.

42. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight greater than about 500,000 daltons.

Appl. No. : 10/789,836
Filed : February 27, 2004

43. (Previously Presented) A transdermal delivery system comprising an ethoxylated oil and a delivered agent that has a molecular weight of 1,000 daltons to 2,000,000 daltons.

44. (Previously Presented) The transdermal delivery system of Claim 43, further comprising water.

45. (Previously Presented) The transdermal delivery system of Claim 43, further comprising an alcohol.

46. (Previously Presented) The transdermal delivery system of Claim 43, wherein said ethoxylated oil comprises an ethoxylated animal oil or an ethoxylated vegetable oil.

47. (Previously Presented) The transdermal delivery system of Claim 43, wherein said ethoxylated oil comprises an oil selected from the group consisting of ethoxylated castor oil, ethoxylated jojoba oil, ethoxylated corn oil, and ethoxylated emu oil.

48. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent is a protein or fragment thereof.

49. (Previously Presented) The transdermal delivery system of Claim 48, wherein the delivered agent is a collagen or a fragment thereof.

50. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent has a molecular weight from about 2,000 daltons to about 500,000 daltons.

51. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent has a molecular weight from about 6,500 daltons to about 205,000 daltons.

52. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 100,000 daltons.

53. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent has a molecular weight from about 300,000 daltons to about 500,000 daltons.

54. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent has a molecular weight greater than about 6,000 daltons.

55. (Previously Presented) The transdermal delivery system of Claim 43, wherein the delivered agent has a molecular weight greater than about 500,000 daltons.

56. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 2,000 daltons to about 2,000,000 daltons.

57. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 5,000 daltons to about 2,000,000 daltons.

Appl. No. : **10/789,836**
Filed : **February 27, 2004**

58. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 10,000 daltons to about 2,000,000 daltons.

59. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 20,000 daltons to about 2,000,000 daltons.

60. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 50,000 daltons to about 2,000,000 daltons.

61. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 100,000 daltons to about 2,000,000 daltons.

62. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 1,000,000 daltons.

63. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 500,000 daltons.

64. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 200,000 daltons.

65. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 100,000 daltons.

66. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 50,000 daltons.

67. (Previously Presented) The transdermal delivery system of Claim 1, wherein the delivered agent has a molecular weight from about 1,000 daltons to about 20,000 daltons.